CYTOKINETICS INC (CYTK)
US23282W6057 - Common Stock
Why Cytokinetics Stock Was a Nearly 5% Winner Today
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 29, 2024 it...
Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that COMET-HF (Confirmation of...
Cytokinetics to Participate in December Investor Conferences
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to...
Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
PDUFA Target Action Date Set for September 26, 2025 SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:...
Notable Wednesday Option Activity: GME, CYTK, AI
Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
Approximately €70 Million in Upfront and Near-term Payments to Cytokinetics Up to €490 Million in Commercial Milestone Payments, withTiered Royalties...
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024
Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen Uptake Recovery and Quality of Life New Data from...
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from post-hoc analyses...
Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to...
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089
Advancement of Fast Skeletal Muscle Troponin Activator Expands Pipeline of Muscle-Directed Drug Candidates SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 ...
Cytokinetics Reports Third Quarter 2024 Financial Results
Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil,and...
Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced six upcoming presentations at...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 31, 2024 it...
Cytokinetics to Announce Third Quarter Results on November 6, 2024
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report...
Cytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day
NDA for Aficamten Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil, and AMBER-HFpEF, Phase 2 Clinical Trial of...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 30, 2024 it...
Cytokinetics to Host Investor & Analyst Day on October 16, 2024
Company Leadership to Discuss Cardiac Myosin Modulation, Specialty Cardiology Programs and Commercial Launch Preparations SOUTH SAN FRANCISCO, Calif.,...
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting
Responder Analyses Show Treatment with Aficamten Demonstrated Improvements on Multiple Assessments of Clinical Significance to Cardiologists Results...
Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from...
Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for...
Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
Analyses of Effects of Aficamten on Key Clinical Outcomes from SEQUOIA-HCM to be Featured in Late Breaking Clinical Trial Presentation at HFSA SOUTH SAN...
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb, just behind Cytokinetics.
Cytokinetics Announces Data From Phase 1 Study of CK-4021586
Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024 SOUTH SAN FRANCISCO, Calif., Sept. ...
Cytokinetics Announces Data From Phase 1 Study of CK-4021586
Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024 SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from the Phase 1 study of CK-4021586 (CK-586) were presented in a poster session at the American College of […]
Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting
Full Data from Phase 1 Study of CK-4021586 to be Presented on September 8, 2024...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 30, 2024 it...
Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024
Data from Integrated Safety Analysis Across Three Clinical TrialsReinforces Robust Safety Profile of Aficamten Analysis from FOREST-HCM...
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024
Additional Data from SEQUOIA-HCM Demonstrate Favorable Cardiac Remodelingby Cardiac MRI, Improvements in Cardiac Structure and Function by...
Cytokinetics to Participate in September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to...
Cytokinetics Larger Than S&P 500 Component Ralph Lauren
CYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q2 2024
CYTK stock results show that Cytokinetics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
CYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cytokinetics (NASDAQ:CYTK) just reported results for the second quarter of 2024...
Cytokinetics Reports Second Quarter 2024 Financial Results
Type B Meeting Held with FDA Related to Potential Risk Mitigation Strategies for Aficamten;Company Has Initiated Rolling NDA Submission FDA Cleared...